# Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Study · id `cardio:ct-nct06307652` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06307652](<https://clinicaltrials.gov/study/NCT06307652>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06307652

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 4005 participants.

## Technical summary

Registry record NCT06307652. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-12 (actual); primary completion 2027-04-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4005 participants (enrolled count; ClinicalTrials.gov record NCT06307652, source copy `cardio:ctgov-nct06307652-2026-11-18`, retrieved 2026-11-18)
- Started: 2024-04-12 (actual) (ClinicalTrials.gov record NCT06307652, source copy `cardio:ctgov-nct06307652-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2027-04-16 (anticipated) (ClinicalTrials.gov record NCT06307652, source copy `cardio:ctgov-nct06307652-2026-11-18`, retrieved 2026-11-18)
- Completion: 2027-04-16 (anticipated) (ClinicalTrials.gov record NCT06307652, source copy `cardio:ctgov-nct06307652-2026-11-18`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Finland; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Peru; Philippines; Poland; Romania; Saudi Arabia; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06307652, source copy `cardio:ctgov-nct06307652-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06307652-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
- Acronym: BalanceD-HF
- Condition: Heart Failure and Impaired Kidney Function
- Intervention (Drug): balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Intervention (Drug): balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Intervention (Drug): dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 0fd33291a10b18523ac500935d7666a9f484226bdd86c061d341def0146b4fb1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
